SynthesisNaunyn-Schmiedeberg's archives of pharmacology2025
Morin, as a natural flavonoid, provides promising influences against cardiovascular diseases.
Synthesis in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Morin Improves Cognitive Deficits in an in Vivo Model of Vascular Dementia by Modulating the N-methyl-D-aspartate Receptor Signaling Pathways.Neurochemical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present investigation evaluated the potential impacts of morin, a natural flavonoid, against cardiovascular disorders. Since inception until September 2024, PubMed, Scopus, and Web of Science have been searched extensively. The process involved eliminating duplicate entries and conducting a systematic review of the remaining studies post-full-text screening. The search was conducted with meticulousness and in adherence to established protocols. Morin has shown various cardioprotective effects in experimental models. It reduces oxidative stress, inflammation, and tissue damage in conditions like myocardial ischemia, injury, and infarction. It also mitigates the harmful effects of toxins and improves hemodynamic parameters, antioxidant levels, and cardiac function. Moreover, it can address conditions like chronic iron overload and metabolic syndrome. Its mechanisms of action involve regulating signaling pathways, promoting autophagy, and reducing oxidative stress and inflammation. Morin hydrate is promising as a therapeutic agent for cardiovascular and related disorders. Morin Hydrate exhibits promising cardioprotective properties, effectively reducing oxidative stress and inflammation in myocardial conditions while also countering the effects of toxins and improving heart function. Additionally, it holds the potential for addressing chronic iron overload and metabolic syndrome. Its multifaceted mechanisms, including signaling pathway regulation and promotion of autophagy, highlight its therapeutic potential for various cardiovascular and related disorders.
Indexed as
Identifiers
39808314What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.